Abstract
Peripheral T cell lymphomas (PTCLs) are heterogeneous neoplasms and represent about 12% of all lymphoid malignancies. They are often regarded as "orphan diseases," a designation that does not reflect their real incidence but rather signifies the difficulties encountered in their classification, diagnosis, and treatment. Here we revise the current understanding of the pathobiological characteristics of the most common nodal PTCLs by focusing on the contribution given by high-throughput technologies and the identification of potential therapeutic targets proposed by translational studies.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use
-
Antibodies, Monoclonal / immunology
-
Antigens, Neoplasm / immunology
-
Antigens, Surface / immunology
-
Gene Expression Profiling
-
Gene Expression Regulation, Neoplastic
-
Histone Deacetylase Inhibitors / therapeutic use
-
Humans
-
Lymphoma, T-Cell, Peripheral / classification
-
Lymphoma, T-Cell, Peripheral / genetics*
-
Lymphoma, T-Cell, Peripheral / pathology
-
Lymphoma, T-Cell, Peripheral / physiopathology
-
MicroRNAs / genetics
-
MicroRNAs / physiology
-
Molecular Targeted Therapy
-
Neoplasm Proteins / antagonists & inhibitors
-
Neoplasm Proteins / genetics*
-
Neoplasm Proteins / physiology
-
Neoplastic Stem Cells / pathology
-
Platelet-Derived Growth Factor / physiology
-
Prognosis
-
Protein Kinase Inhibitors / therapeutic use
-
Receptors, Platelet-Derived Growth Factor / physiology
-
Signal Transduction / genetics
-
Signal Transduction / physiology
-
T-Lymphocyte Subsets / pathology
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antigens, Neoplasm
-
Antigens, Surface
-
Histone Deacetylase Inhibitors
-
MicroRNAs
-
Neoplasm Proteins
-
Platelet-Derived Growth Factor
-
Protein Kinase Inhibitors
-
Receptors, Platelet-Derived Growth Factor